

*NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (DIRECTLY OR INDIRECTLY) IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE TO DO THE SAME WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.*

## Sale of the share warrants ("BSA") allotted to Natraceutical Group for the Naturex capital increase

*Communiqué de presse*

Avignon, October 13<sup>th</sup>, 2011 - In the course of the capital increase (prospectus approved by the AMF n°11-442 on 3<sup>rd</sup> October 2011), NATUREX has been informed on 11<sup>th</sup> October by NATRACEUTICAL GROUP, possessing 31.08% of the share capital and 11.89% of the voting rights before the capital increase, that the Spanish group has sold before the end of the exercise period all of its 1 995 502 BSA.

These BSA have been sold close to the prevailing market price to institutional European investors independent from the concert members and to SGD, possessing 13.08% of the share capital and 16.41% of the voting rights before the capital increase, in line with its undertaking agreement and intentions disclosed before the launch of the capital increase to get 28% of the new shares.

The Company reminds that the BSAs which will not have been exercised will be repurchased according to the terms of the above mentioned prospectus on a Placement price basis, such Placement price resulting from the confrontation of supply for shares issued from the exercise of the Repurchased BSA and purchase demand according to the "bookbuilding process".

### ► Recall of the Intention of the main shareholders

Acting in concert through a shareholding group including, on the one hand Mr. Jacques Dikansky (directly and indirectly through de SGD) and, on the other hand, the "Natraceutical Group" (hereafter the "Dikansky-Natraceutical shareholding group") representing 44.16% of the share capital and 28.30% of the voting rights of Naturex, Mr. Jacques Dikansky, Chairman of the Company, and the SGD, the main shareholder of the Company, jointly holding 840,253 Naturex shares representing 13.08% of the share capital and 16.41% of the voting rights, have irrevocably undertaken to take up this issue by exercising their BSAs and/or purchasing shares through the placement, so that the subscriptions of the Dikansky-SGD-Natraceutical shareholding group represent 28% of the shares issued and that this shareholding group accordingly remains below the threshold 30% of the voting rights of the Company.

**You can receive all of NATUREX's financial information free of charge by signing up on:**  
[www.naturex.com](http://www.naturex.com)

## ► Upcoming events

- Actionaria (Paris) 18-19 november 2011

## ► Next publications

- Q3 2011 sales 04 november 2011
- Q3 2011 results 30 november 2011

Naturex has been listed since October 1996 on NYSE Euronext in Paris, compartment B



Number of shares comprising the capital: 6,421,740

- 5,034,432 ordinary shares (ISIN FR0000054694)
- 1,387,308 preferred shares (ISIN FR0010833251)

Naturex is part of the CAC Small and Gaïa Indexes.

Naturex is eligible for "long only" Deferred Settlement Service (SRD).

MNEMO: NRX - Reuters: NATU.PA - Bloomberg: NRX: FP

## About Naturex

Naturex is the world leader in specialty plant-based ingredients.

The Group, organised around three strategic markets - Food & Beverage, Nutrition & Health and Personal Care -, produces and markets specialty plant-based ingredients for the food, nutraceutical, pharmaceutical and cosmetics industries.

Naturex's head office is based in Avignon. Naturex employs 950 people and has high-performance industrial resources across its 11 industrial sites in Europe (France, Italy, Spain, United Kingdom and Switzerland), in Morocco, the United States, Brazil and Australia. The company draws on its worldwide sales presence through a fully dedicated sales network in 19 countries (France, Italy, Spain, United Kingdom, Belgium, Germany, Switzerland, Russia, U.A.E., Thailand, Singapore, Japan, China, Korea, Australia, United States, Canada, Brazil and Mexico).

Naturex enjoys the highly favourable underlying trend linked to increasing demand for natural-origin products and provides manufacturers with personalised solutions in order to meet the expectations of the end consumers. The Group's strength lies in its positioning on specific products which constitute niche markets, thanks to strong sourcing capacity and sustained Research & Development.

## ► Contacts

### Jacques Dikansky

President and Chief Executive Officer

Tel.: +33 (0)4 90 23 96 89

[naturex@naturex.com](mailto:naturex@naturex.com)

### Thierry Lambert

Vice-President

Tel.: +33 (0)4 90 23 96 89

[t.lambert@naturex.com](mailto:t.lambert@naturex.com)

### Carole Alexandre

Investor Relations

Tel.: +33 (0)4 90 23 78 28

[c.alexandre@naturex.com](mailto:c.alexandre@naturex.com)

### Anne Catherine Bonjour

Actus Finance Press Relations

Tel.: +33 (0)1 53 67 36 93

[acbonjour@actus.fr](mailto:acbonjour@actus.fr)

*This document is a marketing communication and not a prospectus.*

*This press release shall not be distributed, published or released in the United States of America (including its territories and possessions, every State in the United States and the District of Columbia), Australia, Canada or Japan.*

*This press release and the information contained herein do not constitute an offer to sell or to subscribe securities or the solicitation of an offer to buy or subscribe securities in other jurisdictions than France. The release of this press release in certain jurisdictions may be restricted by law. Therefore persons in such jurisdictions into which this press release is released, published or distributed must inform themselves about and observe such restrictions.*

*This press release does not constitute an offer to sell securities or the solicitation of an offer to buy or subscribe to securities in the United States or any other countries. The securities mentioned in this press release have not been and will not be registered under the United States Securities Act of 1933, as amended and may not be offered or sold in the United States or to a US Citizen or for his behalf absent registration or exemption from registration under the Securities Act. There will not be any public offering of securities in the United States of America.*